Clinical Trial Update: A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD [Phase 2]

View source ↗

Summary

Phase II study evaluating the addition of low-dose interleukin-2 to extracorporeal photopheresis for steroid-refractory chronic graft-versus-host disease has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Interleukin-2 (low-dose) (interleukin-2)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Graft-versus-host-disease | Phase 2 | Status: COMPLETED | Results posted: 2018-10-18